 Â¼ .006).37 The pooled analysis of
30-day outcomes of stroke and death were lower for
symptomatic patients treated with CEA vs TF-CAS14 (Fig 1).
The long-term outcomes of CAS vs CEA for symptomatic patients were examined using a preplanned pooled
analysis of individual patient data from the EVA-3S,
SPACE, ICSS, and CREST studies.38 These four trials randomized a total of 